Sign in

You're signed outSign in or to get full access.

TC

TPI COMPOSITES, INC (TPIC)·Q3 2024 Earnings Summary

Executive Summary

  • Q3 2024 delivered sequential improvement: net sales rose 23% vs Q2 to $380.8M and adjusted EBITDA turned positive to $8.0M; however, management cut FY24 adjusted EBITDA margin guidance to approximately -2% from ~+1% due to slower ramp/quality-first transitions, Turkey inflation, and legacy warranty updates .
  • Utilization reached 89% with seven of ten ramping/transition lines at full rate; all regions expected EBITDA-positive in Q4, and Q4 targeted as strongest free cash flow quarter of the year .
  • Strategic catalysts: US demand supports reopening the Iowa plant mid-2025 (two lines, minimal CapEx) and securing additional US brownfield capacity (up to four lines) to serve large projects; 2025 volumes in US expected strong while Turkey/Europe remain challenged by inflation and Chinese competition .
  • Estimates context: S&P Global Wall Street consensus was unavailable at time of analysis, so beat/miss cannot be assessed; company stated Q3 sales were “in line with our expectations and full year guidance” .

What Went Well and What Went Wrong

What Went Well

  • Adjusted EBITDA returned to positive ($8.0M; 2.1% margin) on portfolio reshaping, improved mix/ASPs, and exit of loss-making Matamoros; operating cash flow turned slightly positive ($1.1M) .
  • Utilization reached 89% with 7/10 new lines achieving full rate; management expects all regions EBITDA-positive in Q4 and Q4 to be strongest free cash flow quarter .
  • Strategic US capacity: agreement to reopen Iowa mid-2025 and secured additional brownfield US capacity (up to four lines) to serve large projects; “plants dedicated to the U.S. market are sold out for 2025” .

Quote: “Our third quarter was a big improvement… we were able to post positive adjusted EBITDA and operating cash flows driven by the actions we've taken to restructure our portfolio and transition 10 lines to next-generation workhorse blades.”

What Went Wrong

  • Guidance cut: FY24 adjusted EBITDA margin reduced to ~-2% vs prior +1% on extended, quality-first start-up timelines ($15M lower sales; ~$5M higher start-up/transition costs), Turkey inflation (-$4M), and ~$7M change in estimate for legacy warranties .
  • Turkey/Europe headwinds: hyperinflation in Türkiye reduces competitiveness into EU; Chinese suppliers aggressively expanding; demand expected down ~40% vs prior expectations for contracted lines in Türkiye in 2025 .
  • Elevated interest burden: Q3 interest expense was $24.2M and net debt rose to ~$606M, constraining flexibility despite adequate cash ($126M) .

Financial Results

MetricQ1 2024Q2 2024Q3 2024
Revenue ($USD Millions)$299.1 $309.8 $380.8
Revenue YoY %-26.0% -17.2% +2.8%
Diluted EPS - Continuing Operations ($USD)$(1.31) $(1.30) $(0.81)
Adjusted EBITDA ($USD Millions)$(23.0) $(24.9) $8.0
Adjusted EBITDA Margin %-7.7% -8.0% 2.1%
Utilization %67% 63% 89%

Segment breakdown (net sales from continuing operations):

SegmentQ1 2024 ($USD Millions)Q2 2024 ($USD Millions)Q3 2024 ($USD Millions)
Wind (Blades, Tooling, Other)$288.9 $304.3 $369.1
Field Services$5.1 $5.5 $11.7

KPIs:

KPIQ1 2024Q2 2024Q3 2024
Blade Sets (units)488 473 601
Estimated Megawatts (GW)2.050 2.024 2.526
Utilization %67% 63% 89%
Dedicated Manufacturing Lines36 38 34
Manufacturing Lines Installed36 38 34
Wind Blade ASP ($ thousands)$183 $208 $199

Non-GAAP and balance sheet highlights (Q3):

  • EBITDA $(5.6)M vs Adjusted EBITDA $8.0M (reconciling items include share-based comp, FX, asset impairments, restructuring) .
  • Unrestricted cash $125.9M; net debt $479.2M; total debt (net) $605.8M .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Net Sales from Continuing OperationsFY 2024$1.3B–$1.4B Approximately $1.35B Maintained midpoint
Adjusted EBITDA Margin % (Continuing Ops)FY 2024Approximately +1% (narrowed to low end) Approximately -(2)% Lowered
Utilization %FY 202475%–80% (34 lines) 75%–80% (34 lines) Maintained
Capital ExpendituresFY 2024$25–$30M Approximately $30M Tightened to top end

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1 2024)Previous Mentions (Q2 2024)Current Period (Q3 2024)Trend
US demand & capacityExpect US recovery; Mexico ramps; Iowa restart under evaluation US 2025 volumes “full out”; Mexico near 90% utilization H2 Iowa reopening mid-2025 (2 lines, minor CapEx); additional US brownfield capacity secured Strengthening US trajectory
Europe/Türkiye dynamicsStable ops; monitoring EU permitting/transmission progress EU demand softer; working on future blade models footprint optimization Türkiye hyperinflation, EU competition from Chinese OEMs; 2025 Türkiye volumes -40% vs prior expectations Deteriorating near-term
Supply chain costs/logisticsRaw materials down YoY; logistics managed Materials stable-to-down; modest logistics increase managed Raw materials expected down ~8% YoY in 2025; logistics volatile but impacts minimized Improving cost tailwind
Quality/LEAN executionLean focus; transitions heavy in H1 Quality-first approach slowed Q2 sales by ~$20M Quality-first transitions extended timelines; EBITDA impacted; utilization 89%; all regions EBITDA-positive in Q4 Execution improving; short-term cost
AI/technology initiatives——Physics-informed ML “digital twin” curing optimization project announced Aug 14 Innovation investment rising
Macro/policy/tariffsIRA/domestic content; permitting/transmission reforms Interest rates, permitting, election uncertainty cited Post-election uncertainty; potential tariffs; management sees limited impact; state-level support resilient Uncertain policy backdrop

Management Commentary

  • “Sales for the quarter were $380.8 million… Adjusted EBITDA of $8 million… impacted by our measured approach to transitions/start-ups… ~$15M lower sales; ~$5M higher start-up/transition costs; Turkey inflation (-$4M); ~$7M change in estimate for legacy warranty matters.” — CEO William Siwek .
  • “Utilization in the third quarter jumped to 89%… all our regions are expected to be EBITDA positive in Q4… Q4 strongest free cash flow quarter.” — CEO William Siwek .
  • “We are narrowing our full year 2024 revenue guidance to about $1.35 billion… lowering adjusted EBITDA guidance to a loss of approximately 2%… investments to enable 24/7 schedules in Mexico.” — CFO Ryan Miller .
  • “We have agreed with GE Vernova to reopen our Iowa plant in mid-2025… minimal CapEx… start-up costs a couple million dollars; breakeven EBITDA in 2025 for the site.” — CEO William Siwek .

Q&A Highlights

  • Tariff risk: Contracts generally include tariffs in product cost but specifics vary; management does not anticipate material issues; exploring further US capacity .
  • 2025 EBITDA target: Management still expects top-line growth in 2025, but headwinds (Turkey inflation/demand) limit near-term visibility; update to come with Q4 earnings .
  • Turkey/Europe demand: Combination of lower demand and share shift to Chinese suppliers; regulatory/permitting delays in EU cited .
  • Capacity additions: Iowa reopening with 2 lines ramping in H2 2025; secured US brownfield site (up to 4 lines) in attractive geography; details TBD .
  • Services business: Transitioning techs back to revenue work; moving to EBITDA-positive; expected growth in US and Europe .

Estimates Context

  • S&P Global consensus for Q3 2024 revenue, EPS, and EBITDA was unavailable at time of analysis due to data mapping constraints, so we cannot determine beats/misses versus Street. Company indicated Q3 sales were “in line with our expectations and full year guidance.” Values retrieved from S&P Global were unavailable; consensus comparisons could not be performed .

Key Takeaways for Investors

  • Sequential momentum: Q3 net sales rose to $380.8M (+23% q/q; +2.8% y/y) and adjusted EBITDA turned positive (2.1% margin) as transitions matured and loss-making operations exited .
  • Guidance reset: FY24 adjusted EBITDA margin cut to approximately -2%; watch Q4 execution (all regions EBITDA-positive, strongest FCF quarter) and Q4 call for formal 2025 guidance — potential stock catalyst on margin/FCF trajectory .
  • US-driven growth: Plants dedicated to the US are sold out for 2025; reopening Iowa mid-2025 and adding US brownfield capacity underpin volume growth with minimal CapEx at Iowa, supportive of margin recovery .
  • Turkey/EU headwinds: Türkiye inflation and EU competitive pressure (China) drove guidance change and create 2025 volume uncertainty (Turkey down ~40% vs prior expectations). Monitor strategic alternatives for Turkey operations .
  • Cost tailwinds: Raw materials expected down ~8% YoY in 2025; logistics volatility being managed — supports margin recovery as quality/LEAN initiatives sustain .
  • Balance sheet watch: Q3 interest expense $24.2M and net debt ~$479M; cash $125.9M. Execution on Q4 FCF and 2025 EBITDA path is critical to sentiment .
  • Innovation optionality: AI-enabled “digital twin” curing project signals ongoing process technology investment that could enhance quality/productivity structurally .